FY2025 · ended Dec 31, 2025 · Revenue $2,183 · Filed Apr 15, 2026
Aibotics, Inc. (AIBT) files with the SEC under industry code 2833, Medicinal Chemicals & Botanical Products. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $2,183 and a net loss of $2.2 million.
Revenue (TTM)
$0
Net income (TTM)
$-2.09M
-3.2% vs year-ago TTM
Operating cash flow (TTM)
$-348,602
-21.2% vs year-ago TTM
Free cash flow
$-656,620
-175.6% vs prior year
EPS
—
Dividend per share
None
Shares outstanding
567.70M
+1229.8% vs prior year
Net cash
—
Operating margin
-84501.7%
FY 2025
Company profile
- Industry
- Medicinal Chemicals & Botanical Products (SIC 2833)
- Listed as
- AIBT (OTC)
- Fiscal year ends
- December 31
- Incorporated in
- NV
- Headquarters
- Heyburn, ID
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1763329
- Former names
- Mycotopia Therapies, Inc. (until Dec 17, 2024); 20/20 Global, Inc. (until May 19, 2021)
Other Medicinal Chemicals & Botanical Products companies
- Definium Therapeutics, Inc. DFTX
- Regencell Bioscience Holdings Ltd RGC
- Curaleaf Holdings, Inc. CURLF
- Trulieve Cannabis Corp. TRLV
- Cronos Group Inc. CRON
- TFA Therapeutics, Inc. RAJAF
- Tilray Brands, Inc. TLRY
- SNDL Inc. SNDL
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $2,183 | — | — | — | — |
| Operating income | -$1.8M | -$1.6M | -$616,724 | -$1.7M | -$5.0M |
| Net income | -$2.2M | -$1.8M | -$1.2M | -$2.6M | -$5.1M |
| Operating cash flow | -$458,240 | -$259,037 | -$106,765 | -$656,620 | -$235,482 |
| Free cash flow | — | — | — | -$656,620 | -$238,228 |
| Total assets | $874,673 | $1.5M | $2.2M | $387,395 | $1.3M |
| Total liabilities | $4.8M | $4.9M | $4.2M | $1.3M | $1.2M |
| Stockholders' equity | -$4.0M | -$3.4M | -$2.0M | -$891,348 | $52,021 |
| Cash and investments | $255,940 | $185,097 | $279,134 | $385,899 | $1.3M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Material agreement, Acquisition or sale of assets
|
Oct 16, 2026 | Oct 14, 2026 |
| 8-K |
Current report
Material agreement
|
Oct 5, 2026 | Oct 2, 2026 |
| 10-Q | Quarterly report | Aug 19, 2026 | Jun 30, 2026 |
| 10-Q | Quarterly report | Jun 9, 2026 | Mar 31, 2026 |
| 10-K | Annual report | Apr 15, 2026 | Dec 31, 2025 |
| 10-Q | Quarterly report | Nov 19, 2025 | Sep 30, 2025 |
All 110 Aibotics, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.